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Case Report
AbstractTreatment of multiresistant ovarian cancer is palliative and patients have needs forless toxic treatment. Anti-angiogenic treatments have a less toxic profile, andbevacizumab has shown improvement of progression free survival (PFS) infront-line trials. Bevacizumab is generally introduced in combination withchemotherapy; however this case report will describe the use of single-agentbevacizumab for more than five years (102 cycles) in a patient with relapse ofadvanced ovarian cancer.
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1. IntroductionIn Denmark 500 new cases of ovarian cancer (OC) areregistered yearly. Approximately 75% of the womenhave advanced disease at the time of diagnosis (stageII-IV) and around 70-85% will have initial response totreatment. Nevertheless 80% will experience relapse,often within 2 years after first-line chemotherapy, andthe chance of cure is small.1,2 Over time patients developchemotherapy resistance and there is an obvious needfor biological treatment without hematological toxicityside effects. Biological treatment regimens, includinganti-angiogenic therapy have the advantage of rarehematological toxicity.Bevacizumab treatments have been investigated inseveral studies and have shown improvement of PFS inboth first and second/third line treatment although it isprobably with more striking effect in patients withrecurrence.3 Bevacizumab has been approved in Europefor first-line treatment when administered in addition tocarboplatin and paclitaxel and as maintenance therapyafter completion of the chemotherapy based on twopivotal phase III studies, ICON7 and GOG218.4,5,6Two further studies in ovarian cancer patients withrecurrent cancer have also been published.7,8 The firststudy (OCEANS) included patients withplatinum-sensitive disease, while the second study(AURELIA) was in platinum-resistant disease. Thesestudies looked at the effect of adding bevacizumab to acombination regime with carboplatin and gemcitabineor to paclitaxel, topotecan, or pegylated liposomal
doxorubicin and both studies indicated an improved PFSin patients treated with the addition of bevacizumab tochemotherapy. The hallmark of these large studies andthe approved indication is the combination withchemotherapy. Since patients with recurrence of diseaseoften have a poorer performance status and differentrequirements for quality of life in palliation of alife-threatening disease, it is highly relevant to examinetreatments with less side-effects including thepossibility of single-agent bevacizumab treatment whichis much less well documented.
2. Case PresentationA 55-year-old post-menopausal woman debuted in 2004with pleural effusion. Pleural effusion cytology wasinvestigated by immonohistochemistry. Abdominalultrasound found discreet amount of ascites without anyovarian pathology described. Physical exam was normal.Furthermore, computed tomography of thorax, abdomenand pelvis were without any sign of primary tumor.Since it was not possible to detect the primary tumor thepatient was considered to have lung cancer and treatedwith standard platinum and vinorelbine. After the firstdose the patient developed febrile neutropenia, and thesecond dose was reduced. Despite dose reduction thepatient developed pancytopenia and subsequent cycleswere delayed several times. After 6 cycles, a CT scanshowed that the patient had complete remission and thepatient entered the follow-up program. In February2007 the patient discovered lower abdominal fullness,and was diagnosed with grade 3, mixed serous/clear cell
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OC, stage IIIC. She underwent surgery with totalhysterectomy, bilateral salpingo-oophorectomy andomentectomy. The surgery was not complete as a 3 cmlarge tumor nodule was left above the liver. A pathologyreexamination of the previous pleural effusion andpresent tumor was performed and showed that thetissues had the same morphology, concluding that thepatient now had relapse from a previous OC.Post-operatively, the patient received first-linetreatment carboplatin and paclitaxel at a reduced dosedue to the previous incidence of pancytopenia. Paclitaxelwas withdrawn after the second dose due tohematological toxicity. The patient continuedcarboplatin monotherapy, and despite supplementaryfilgrastim the treatment was delayed due topancytopenia. After 4 doses of carboplatin the treatmentwas changed to gemcitabine, but since the patient againdeveloped pancytopenia she was referred to follow-up.In June 2008, after a treatment-free interval of 8.8months the patient was diagnosed with progression andliver metastases and referred to experimental treatmentwith single-agent bevacizumab in the hope for bettertolerance.In July 2008 single-agent bevacizumab treatment wasinitiated (10 mg/kg intravenous infusion) on day 1 of a21 days cycle. Serum cancer-related antigen 125(CA125) at baseline was 49 U/mL (normal range 0-35).After 3 doses of bevacizumab CA125 dropped to 8 U/mLand remained stable (range 8-11) until September 2012.After 4 years of treatment (70 doses) bevacizumab waspaused because the patient needed surgery formitral-valve-disease. In February 2013 after a 6 months’
treatment pause, CA125 had increased to 290 U/mL, anda CT scan verified progression. Bevacizumab treatmentwas reintroduced in March 2013, and CA125 dropped to65 U/mL after the first 3 cycles of re-induction and thepatient stayed on treatment for an additional 32 cycleswith hardly any side effects (Figure 1). The patienttolerated the treatment without any significant toxicitiesand reported a good quality of life during treatment. InDecember 2014 after a total of 102 cycles ofbevacizumab CA125 progressed to 231 U/mL and a CTscan confirmed progression, and third-line treatmentwith doxorubicin was introduced in February 2015 withCA125 response but with a new CA125 progression after8 cycles of treatment..
3.DiscussionKnowledge about single-agent bevacizumab in womenwith recurrent OC is limited since most studies haveevaluated bevacizumab in combination with standardchemotherapy regimens. Two trials7,8 on relapsetreatment allowed single-agent bevacizumab untilprogression, 10 mg/kg every 2 weeks and 15 mg/kgevery 3 weeks, respectively. However, only a fewpatients received long-term bevacizumab maintenance.The longest duration was 24 and 37 treatments,respectively.7,8 Bevacizumab single agent treatment forrecurrent OC is described in the literature with a dose of15 mg/kg every 3 weeks with 16 and 35 cycles as thehighest number of cycles reported.9,10 A single studydescribes long term effect with one patient havingreceived treatment for a period of more than 21 monthsand still ongoing at the time of publication.10
Figure 1: CA125 level during single treatment with bevacizumab, 10 mg/kg every 3 weeks. Treatment was paused for 6months, during September 2012 until February 2013 - illustrated with the two vertical black lines.
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The patient in this case report was treated with singleagent bevacizumab 10 mg/kg every three weeks for 5½years. This treatment managed to keep the diseasestable despite the lower dose compared to severalpublished trials. The disease progressed duringtreatment pause, and when bevacizumab wasreintroduced, the tumor responded again. This supportsthe assumption that the patient clearly has underlyingcancer disease, which bevacizumab was able to keepstable. Our patient was initially treated with differentchemotherapy regimens, all causing severehematological toxicity and repeated treatment delays.During the treatment with bevacizumab there were noside-effects and the patient benefited from the treatmentfor several years.It is our experience that patients with advanced OC canbenefit from single-agent bevacizumab. This case wasexceptional in keeping the cancer stable for more than 5years, which has not previously been described in theliterature.
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